Research Areas

Stratagene and the Sidney Kimmel Cancer Center (SKCC) announced in mid-April a licensing agreement covering patents and related technology developed by SKCC researcher Dr. Gennadi Glinsky, under which Stratagene will produce diagnostic tests for prostate and breast cancers.

With an eye to developing therapeutics against neurodegenerative disease, Applied NeuroSolutions (ANS) recently joint-licensed a transgenic mouse line with the not-for-profit Research Foundation for Mental Hygiene at the Nathan S. Kline Research Institute that exhibits human disease pathology.

Applied Biosystems in mid-March introduced a new plan, the Advanced Gene Expression Service Provider Program (AGESPP), to sell varying combinations of instrumentation, supplies, services, and marketing support in custom-made bundles at discounted prices.

RNAi biopharmaceutical company Alnylam took another step on the road to moving its age-related macular degeneration (AMD) and respiratory syncytial virus (RSV) infection programs closer to clinical trials in late March by naming Dowpharma its manufacturer-of-choice for large-scale quantities of short interfering RNAs (siRNAs).

Although biopharmaceutical firm Adherex already has a promising N-cadherin antagonist currently in clinical trials, that drug candidate lacks a very important aspect: the ability to be administered orally.

Metabolon Inc. in early April announced it received a grant from the National Institute of Environmental Health Sciences (NIEHS) for its continued research into the discovery of biomarkers for amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease.

Bionaut Pharmaceuticals and AnalytiCon Discovery of Potsdam, Germany, announced in April a service and collaboration agreement to identify novel anti-cancer compounds that inhibit the ability of tumor cells to survive stress conditions.

MultiCell Technologies, which develops liver cell-based products for commercial and therapeutic applications, relocated its offices and laboratory into larger, more modern facilities in mid-April.

Before most people ever get to experience the relief offered by prescription medicines, they first spend time with a physician who runs a battery of tests to identify the patient’s medical condition. Historically, these two processes—diagnosis and treatment—have evolved from different directions. One set of clinicians examined thousands of patients to correlate specific medical manifestations (symptoms) with specific medical conditions (diseases), while other

Business is business. It is a mantra that has guided much of my adult life. A life spent writing news about a diversity of industries —everything from home medical equipment and security, to custom home entertainment systems and gourmet food. Yet, soon after I jumped on board to help start Drug Discovery News, I wavered and considered abandoning that mantra. Because here was an industry that seemed just out of reach, one that dealt in the nearly intangible. I understand the market for a good chunky salsa or a